Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: A first-in-human study

Journal of Clinical Pharmacology

Volumn 43, Issue 4, 2003, Pages 406-413

  Parasrampuria, Dolly A ^a,b,c   De Boer, Peter ^a   Desai Krieger, Daksha ^a   Chow, Andrew T ^a   Jones, C Richard ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NONE   (United States)

Author keywords

Biomarker; Mitogen activated protein kinases; Pharmacodynamics; Pharmacokinetics; RWJ 67657

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FLATULENCE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; IC 50; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NAUSEA; NORMAL HUMAN; PAIN; PHARMACODYNAMICS; POLYMORPHONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOOD-DRUG INTERACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES;

EID: 0037380693     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002250615     Document Type: Article

References (14)

1. Kummer JL, Rao PK, Heidenreich KA: Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Bio Chem 1997;272:20490-20494.
2. Chen J-J, Sun Y, Nabel GJ: Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998;282:1714-1717.
3. de Bock F, Derijard B, Dornand J, Bockaert J, Rondouin G: The neuronal death induced by endotoxic shock but not that induced by excitatory amino acids requires TNF-alpha. Eur J Neurosci 1998;10: 3107-3114.
4. Zhu W, Zou Y, Aikawa R, Harada K, Kudoh S, Uozumi H, et al: MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 1999;100:2100-2107.
5. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
6. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowly S, Hsuan J, et al: Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994;78:1039-1049.
7. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G, et al: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996;15:1914-1923.
8. Baldassare JJ, Bi Y, Bellone CJ: The role of p38 mitogen-activated protein kinase in IL-1β transcription. J Immunol 1999;162:5367-5373.
9. Shieh JC, Wilkinson MG, Millar JB: The Win1 mitotic regulator is a component of the fission yeast stress-activated Sty1 MAPK pathway. Mol Biol Cell 1998;9:311-322.
10. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, et al: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Bio Chem 1997;272: 12116-12121.
11. Wysk M, Yang DD, Lu H-T, Flavell RA, Davis RJ: Requirement of mitogen-activated protein kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Nat Acad Sci USA 1999;96:3763-3768.
12. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, et al: RWJ 67657, a potent, orally active inhibitor of p38 mitogen activated protein kinase. J Pharmacol Exp Ther 1999;291: 680-687.
13. Fullerton T, Sharma A, Prabhakar U, Tucci M, Boike S, Davis H, et al: Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase. Clin Pharmacol Ther 2000; 67:114.
14. Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell 1996;85:307-310.